The Cognitive and Cerebral Blood Flow Effects of Resveratrol

Not Applicable

Completed

• Conditions: Cognitive and Cerebral Blood Flow Effects of Resveratrol
• Interventions: Dietary Supplement: Trans- resveratrol; Other: Placebo (silica)

• Registration Number: NCT01010009
• Lead Sponsor: Northumbria University

Brief Summary

Research shows that resveratrol is able to induce vasodilation (and therefore blood flow) by interacting with nitric oxide (NO). Research also shows that acute administration of metabolic substrates, like oxygen and glucose, can enhance aspects of cognitive performance in young, healthy humans. The aim of this investigation was to determine if the consumption of resveratrol could modulate cerebral blood flow and if this in turn could influence cognitive performance by increasing access to blood borne metabolic fuel. Results showed that compared to placebo, after consuming 500mg pure trans-resveratrol, levels of total haemoglobin were significantly higher in the frontal cortex of young, healthy participants during cognitive task completion. Cognitive performance was not effected.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-06
• Primary Completion: 2009-03
• Study Completion: 2009-03
• Study First Submitted: 2009-11-06
• Study First Submitted QC: 2009-11-06
• Study First Posted: 2009-11-09
• Results First Submitted: 2010-06-26
• Results First Submitted QC: 2011-03-16
• Results First Posted: 2011-04-18
• Status Verified: 2012-05
• Last Update Submitted: 2012-05-17
• Last Update Posted: 2012-05-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Male/female,
• Healthy
• Age 18-35 years old
• Non smoker
• Proficient in English
• Not taking any herbal or prescription medications
• Not pregnant
• Does not drink more than 6 cups of coffee per day

Exclusion Criteria

• Suffered a head injury, neurological disorder or neuro-developmental disorder
• Food allergies/intolerances

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo (silica)	-
Resveratrol 250mg	Trans- resveratrol	-
Placebo	Trans- resveratrol	-
Resveratrol 250mg	Placebo (silica)	-
Resveratrol 500mg	Trans- resveratrol	-
Resveratrol 500mg	Placebo (silica)	-

Primary Outcome Measures

Name	Time	Method
Modulation of Deoxygenated Levels of Haemoglobin	0-81 mins (absorption period=1- 45 mins , post dose period 46- 81 mins)	This outcome measure provides the change from baseline values (in µmol/L) of levels of deoxygenated haemoglobin during the 46-81 min post dose testing period. This was measured in the frontal cortex by near infrared spectroscopy (NIRS).
Modulation of Levels of Total Haemoglobin	0-81 mins (absorption period=1- 45 mins , post dose period 46- 81 mins)	This outcome measure provides the change from baseline values (in µmol/L) of total levels of haemoglobin during the 46-81 min post dose testing period. This was measured in the frontal cortex by near infrared spectroscopy (NIRS).

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Significant Modulation of Cognitive Performance	46-81 mins post dose	This outcome measure assessed any significant modulation of cognitive task performance during the 46-81 min post dose period. The cognitive tasks utilized were cognitively demanding computer based, numerical tasks which assessed working memory. Significant modulation is defined as significant difference between baseline and post-dose task performance.

Trial Locations

Locations (1)

Northumbria University; 🇬🇧 Newcastle upon Tyne, United Kingdom